Quartet Medicine, a pain and inflammation treatment company, secured the funds from backers including Pfizer, Novartis and Partners Innovation Fund.
Quartet Medicine, a US-based developer of treatments for chronic pain and inflammation, has raised $17m in a series A round from a consortium including pharmaceutical firms Novartis and Pfizer.
Novartis Venture Funds, Pfizer Venture Investment and the Brigham and Women’s Hospital and Massachusetts General Hospital-funded Partners Innovation Fund all participated as new investors. Henry Skinner from Novartis Venture Funds has joined Quartet’s board.
Venture capital firm Atlas Venture led the round, having provided the seed money in late 2013 to…